<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03743259</url>
  </required_header>
  <id_info>
    <org_study_id>HL_LMN_201</org_study_id>
    <nct_id>NCT03743259</nct_id>
  </id_info>
  <brief_title>To Evaluate the Efficacy and Safety of LuminoMark Injection in Patients With Nonpalpable Breast Lesions</brief_title>
  <official_title>A Multicenter, Open-label, Parallel, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of LuminoMark Inj. (Conc. for Fluorescence) Localization in Patients With Nonpalpable Breast Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, Open-label, Parallel, Phase 2 Clinical Trial in 6 weeks for
      screening, once Investigational product injection, Follow up visit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of LuminoMark inj. (Conc.
      for fluorescence) localization in patients with nonpalpable breast lesions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 29, 2018</start_date>
  <completion_date type="Actual">April 22, 2019</completion_date>
  <primary_completion_date type="Actual">January 11, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Excision perfection(It is a formula. This formula's calculation method is as follows. [Excision perfection = the longest diameter of removed lesion after surgery / the longest diameter of identified lesion via breast ultrasonography results])</measure>
    <time_frame>Visit 3(Day 0)</time_frame>
    <description>Excision perfection is how well the surgeon removed the lesion compared to an identified by breast ultrasonography. Visit 3, Investigators calculate 'Excision perfection' using by the formula.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Coloring confirmation rate of excision lesion.</measure>
    <time_frame>Visit 3(Day 0)</time_frame>
    <description>The proportion of colored excision lesion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Technical success rate</measure>
    <time_frame>Visit 3(Day 0)</time_frame>
    <description>The proportion of colored lesion when make an incision</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pathologic perfection(It is a formula. This formula's calculation method is as follows. [Pathologic perfection = the longest diameter of measured lesion by gross(=visual) pathologic method / the longest diameter of removed lesion after surgery])</measure>
    <time_frame>Visit 3(Day 0)</time_frame>
    <description>Pathologic perfection is how well the surgeon removed the lesion compared to an identified by gross pathologic method. Visit 3, Investigators calculate 'Pathologic perfection' using by the formula.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pigmentation</measure>
    <time_frame>Visit 5(Day 10~Day 24)</time_frame>
    <description>Check whether skin is pigmented or not</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Breast Diseases</condition>
  <arm_group>
    <arm_group_label>LuminoMark inj. 0.1mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection LuminoMark inj. 0.1mL once in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LuminoMark inj. 0.2mL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injection LuminoMark inj. 0.2mL once in this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Charcotrace Inj.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Charcotrace Inj. about 0.3~1mL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LuminoMark inj. 0.1mL</intervention_name>
    <description>Injection LuminoMark inj. (Conc. for fluorescence) 0.1mL once in this study.</description>
    <arm_group_label>LuminoMark inj. 0.1mL</arm_group_label>
    <other_name>LuminoMark inj.(Conc. for fluorescence) 0.1mL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LuminoMark inj. 0.2mL</intervention_name>
    <description>Injection LuminoMark inj. (Conc. for fluorescence) 0.2mL once in this study.</description>
    <arm_group_label>LuminoMark inj. 0.2mL</arm_group_label>
    <other_name>LuminoMark inj.(Conc. for fluorescence) 0.2mL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Charcotrace Inj.</intervention_name>
    <description>Injection Charcotrace Inj. about 0.3~1mL once in this study.</description>
    <arm_group_label>Charcotrace Inj.</arm_group_label>
    <other_name>Charcotrace Injection(Activated Charcoal 40mg/1ml)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female, 19 years ≤ age ≥ 80 years

          2. Those who be expected to do operation about non palpable breast lesion excision

          3. Those who have lesion vial mammography and breast ultrasound

          4. Written consent voluntarily to participate in this clinical trial

        Exclusion Criteria:

          1. Patients who be expected to do mastectomy

          2. Patients with multiple tumor or diffuse microcalcification

          3. Patients who have ink on invasive cancer or ductal carcinoma in situ despite 3 times
             local resection

          4. Patients who were treated with moderate to severe radiotherapy

          5. Patients who were treated with neoadjuvant Chemotherapy

          6. Patients with active invading skin connective tissue disease

          7. Patients with local progressing breast cancer or inflammatory local progressing breast
             cancer

          8. Patients who have an allergy to investigational product or any of the component with
             the Investigational product

          9. Patients who disagree about contraception for this clinical trial

         10. A pregnant women or lactating women

         11. Patients who participated in other clinical trials within the past 12 weeks from the
             date of informed consent

         12. Patients who investigators determines unsuitable for this clinical trial
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only female</gender_description>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seok Won Kim, PI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nonpalpable Breast Lesions</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Charcoal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

